Question special
Resident

Many patients take Antiplatelets and/or NSAIDs (including 22.8% of the individuals enrolled in the trial). Just curious to see if the major bleeding events seen in the Apixaban Group were more prevalent with those who also were taking Antiplatelets and/or NSAIDS?